PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript. Topics covered by Dr. Anzalone include Arrowhead’s operational and clinical progress with its RNAi, obesity and regenerative medicine programs, the Company’s paradigm shifting technologies under development, strategic growth initiatives and key catalysts for which investors and industry experts should watch for in the near-term.